Phaseline

Targets › TPH2

TPH2 (Tryptophan 5-hydroxylase 2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Neurology, Oncology; next expected readout Dec 2026.

Neuron-specific enzyme that catalyzes the conversion of L-tryptophan into 5-hydroxy-L-tryptophan, the rate-limiting step in serotonin production, using Fe(2+) as cofactor and molecular oxygen and tetrahydrobiopterin (BH4) as cosubstrates. Plays a crucial role in regulating mood, anxiety and sleep (By similarity). (UniProt, Q8IWU9)

Open in Phaseline: the race on TPH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
M.D. Anderson Cancer CenterTelotristat Ethyl
Tryptophan 5-hydroxylase inhibitor
TPH2, TPH1Phase 3Locally Advanced Neuroendocrine NeoplasmAug 2028
University of Alberta5-Hydroxytryptophan
Serotonin precursor; converted to serotonin by aromatic L-amino acid decarboxylase
TPH1, TPH2Phase 2Spinal Cord InjuriesDec 2026

Conditions

Spinal Cord Injuries (1) Locally Advanced Neuroendocrine Neoplasm (1)

Modalities

small molecule (2)

Companies

University of Alberta (1) M.D. Anderson Cancer Center (1)

Related targets

TPH1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.